Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

被引：0

作者：

Bewersdorf, Philipp ^{[1
,2
]}

Kewan, Tariq ^{[3
]}

Blaha, Ondrej ^{[4
,5
,6
]}

Stahl, Maximilian ^{[7
]}

Al Ali, Najla H. ^{[8
]}

DeZern, Amy E. ^{[9
]}

Sekeres, Mikkael A. ^{[10
]}

Uy, Geoffrey L. ^{[11
]}

Carraway, Hetty E. ^{[12
]}

Desai, Pinkal ^{[13
]}

Griffiths, Elizabeth A. ^{[14
]}

Stein, Eytan M. ^{[15
]}

Brunner, Andrew M. ^{[16
]}

McMahon, Christine M. ^{[17
]}

Zeidner, Joshua F. ^{[18
]}

Savona, Michael R. ^{[19
]}

Stempel, Jessica M. ^{[20
]}

Chandhok, Namrata Sonia ^{[21
]}

Ramaswamy, Rahul ^{[22
]}

Roboz, Gail J. ^{[23
]}

Rolles, Benjamin ^{[24
]}

Wang, Eunice S. ^{[14
]}

Harris, Amyah C. ^{[25
]}

Amaya, Maria L. ^{[26
]}

Hawkins, Hayley ^{[27
]}

Grenet, Justin ^{[28
]}

Gurnari, Carmelo ^{[29
]}

Shallis, Rory M. ^{[30
]}

Xie, Zhuoer ^{[31
]}

Maciejewski, Jaroslaw P. ^{[29
]}

Sallman, David A. ^{[31
]}

Della Porta, Matteo Giovanni ^{[32
]}

Komrokji, Rami S. ^{[8
]}

Zeidan, Amer M. ^{[33
,34
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Yale Univ, Sect Hematol, Dept Med, New Haven, CT USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, New Haven, CT USA

[4] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[5] Yale Univ, Sch Publ Hlth, Yale Ctr Analyt Sci, New Haven, CT USA

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Dana Farber Inst, Boston, MA USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[9] Johns Hopkins Univ, Baltimore, MD USA

[10] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[11] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[13] Weill Cornell Med, New York, NY USA

[14] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[15] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[16] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA

[17] Univ Colorado, Div Hematol, Sch Med, Aurora, CO USA

[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[19] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA

[20] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[21] Univ Miami, Div Hematol, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[22] Washington Univ, St Louis, MO USA

[23] New York Presbyterian Hosp, New York, NY USA

[24] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[25] Dana Farber Canc Inst, Boston, MA USA

[26] Univ Colorado, Div Hematol, Aurora, CO USA

[27] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[28] Weill Cornell, New York, NY USA

[29] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[30] Yale Univ, Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[31] H Lee Moffitt Canc Inst, Tampa, FL USA

[32] IRCCS, Ctr Canc, Humanitas Res Hosp, Milan, Italy

[33] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[34] Smilow Canc Hosp, New Haven, CT USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178728

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[1] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
Zeidan, Amer M.
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Barnard, John
Al Ali, Najla H.
Zimmerman, Cassie
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Jabbour, Elias
Kantarjian, Hagop
Zell, Katrina
Wang, Quiqing
Gore, Steven D.
Nazha, Aziz
Maciejewski, Jaroslaw P.
List, Alan F.
Komrokji, Rami S.
BLOOD, 2014, 124 (21)
[2] Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database
Bewersdof, Jan Philippe
Kewan, Tariq
Blaha, Ondrej
Stahl, Maximilian
Al Ali, Najla H.
DeZern, Amy E.
Sekeres, Mikkael A.
Uy, Geoffrey L.
Carraway, Hetty E.
Desai, Pinkal
Griffiths, Elizabeth A.
Stein, Eytan M.
Brunner, Andrew M.
McMahon, Christine M.
Zeidner, Joshua F.
Savona, Michael R.
Stempel, Jessica M.
Chandhok, Namrata Sonia
Logothetis, Constantine
Roboz, Gail J.
Rolles, Benjamin
Wang, Eunice S.
Harris, Amyah C.
Amaya, Maria L.
Hawkins, Hayley
Grenet, Justin
Shallis, Rory M.
Xie, Zhuoer
Maciejewski, Jaroslaw P.
Sallman, David A.
Della Porta, Matteo Giovanni
Komrokji, Rami S.
Zeidan, Amer M.
BLOOD, 2023, 142
[3] Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
Mufti, Ghulam J.
Silverman, Lewis R.
Best, Steven
Fructman, Steve
Azarnia, Nozar
Petrone, Michael E.
Garcia-Manero, Guillermo
BLOOD, 2015, 126 (23)
[4] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan, Amer M.
Hu, Xin
Long, Jessica B.
Wang, Rong
Huntington, Scott F.
Podoltsev, Nikolai Alexandrovich
Giri, Smith
Stahl, Maximilian
Gore, Steven
Ma, Xiaomei
Davidoff, Amy J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo plus Hypomethylating Agent (HMA)
Zeidan, Amer M.
Fenaux, Pierre
Han, Xia
James, David A.
Malek, Kamel
Ramos, Pedro Marques
Miyazaki, Yasushi
Platzbecker, Uwe
BLOOD, 2023, 142
[6] Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
Bewersdorf, Jan Philipp
Wei, Wei
Jaiani, Anna
Patel, Prital
Mehta, Rajni
Neparidze, Natalia
Shallis, Rory M.
Podoltsev, Nikolai
Brunner, Andrew M.
Zeidan, Amer M.
BLOOD, 2021, 138 : 3701 - +
[7] Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System
Moore, Kristin J.
Engel-Nitz, Nicole M.
McMahon, Peter
Beal, Jason
Jhaveri, Teraneh Z.
Williamson, Mellissa
Andrade, Katherine
Landis, Christina
Sadek, Islam
Hogea, Cosmina
BLOOD, 2023, 142
[8] Higher-Risk Myelodysplastic Neoplasms (HR-MDS) Patient Characteristics in a Large, Integrated United States (US) Healthcare System
Moore, Kristin
Engel-Nitz, Nicole
McMahon, Peter
Beal, Jason
Jhaveri, Tizzy
Williamson, Mellissa
Andrade, Kate
Landis, Christina
Hogea, Cosmina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S365 - S365
[9] The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
Zeidan, Amer M.
Al Ali, Najla H.
Kharfan-Dabaja, Mohamed A.
Padron, Eric
Zhang, Ling
Epling-Burnette, Pearlie K.
Lancet, Jeffrey E.
List, Alan F.
Komrokji, Rami S.
BLOOD, 2013, 122 (21)
[10] Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
Jill A. Bell
Aaron Galaznik
Marlo Blazer
Huai-Che Shih
Eileen Farrelly
Augustina Ogbonnaya
Michael Eaddy
Robert J. Fram
Douglas V. Faller
PharmacoEconomics - Open, 2019, 3 : 237 - 245

← 1 2 3 4 5 →